Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Forde

Showing results (11-20 of 157) with videos related to

Pageof 16
Sort By:
Translational Lung Cancer Research|January 23, 2016
Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet needKristen A Marrone, Patrick M Forde
Expert Opinion on Pharmacotherapy|May 19, 2012
Crizotinib in the treatment of non-small-cell lung cancerPatrick M Forde, Charles M Rudin
Expert Review of Anticancer Therapy|June 19, 2013
Targeted therapy for non-small-cell lung cancer: past, present and futurePatrick M Forde, David S Ettinger
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2020
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung CancerVincent K Lam, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|October 2, 2020
Immunotherapy for mesothelioma: rationale and new approachesJoshua E Reuss, Patrick M Forde
The Oncologist|July 16, 2013
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapiesPatrick M Forde, Ronan J Kelly
The International Journal of Targeted Therapies in Cancer|June 25, 2013
Abiraterone for the Treatment of Advanced Prostate CancerPatrick M Forde, Emmanuel S Antonarakis
Nature Reviews. Clinical Oncology|October 19, 2019
Immunotherapy trials in mesothelioma - promising results, but don't stop hereAnna K Nowak, Patrick M Forde
The New England Journal of Medicine|November 19, 2025
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. ReplyPatrick M Forde, Mariano Provencio, Nicolas Girard
The New England Journal of Medicine|August 10, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. ReplyPatrick M Forde, Jonathan Spicer, Nicolas Girard
Pageof 16

Showing results (11-20 of 157) with videos related to

Sort By:
Pageof 16
Translational Lung Cancer Research|January 23, 2016
Nivolumab for refractory metastatic squamous non-small-cell lung cancer: fulfilling an unmet needKristen A Marrone, Patrick M Forde
Expert Opinion on Pharmacotherapy|May 19, 2012
Crizotinib in the treatment of non-small-cell lung cancerPatrick M Forde, Charles M Rudin
Expert Review of Anticancer Therapy|June 19, 2013
Targeted therapy for non-small-cell lung cancer: past, present and futurePatrick M Forde, David S Ettinger
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2020
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung CancerVincent K Lam, Patrick M Forde
Clinical Advances in Hematology & Oncology : H&O|October 2, 2020
Immunotherapy for mesothelioma: rationale and new approachesJoshua E Reuss, Patrick M Forde
The Oncologist|July 16, 2013
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapiesPatrick M Forde, Ronan J Kelly
The International Journal of Targeted Therapies in Cancer|June 25, 2013
Abiraterone for the Treatment of Advanced Prostate CancerPatrick M Forde, Emmanuel S Antonarakis
Nature Reviews. Clinical Oncology|October 19, 2019
Immunotherapy trials in mesothelioma - promising results, but don't stop hereAnna K Nowak, Patrick M Forde
The New England Journal of Medicine|November 19, 2025
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. ReplyPatrick M Forde, Mariano Provencio, Nicolas Girard
The New England Journal of Medicine|August 10, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. ReplyPatrick M Forde, Jonathan Spicer, Nicolas Girard
Pageof 16